Median Technologies, a global leader in AI-powered imaging solutions for oncology and the developer of eyonis® - its suite of Software as a Medical Device (SaMD) for early cancer diagnosis - has appointed Didric Cederholm to its Board of Directors.
His appointment was formally approved during the Company’s ordinary shareholders’ meeting. Cederholm now joins the Board under the chairmanship of Oran Muduroglu.
Cederholm’s addition to the Board marks an important step for Median Technologies as the Company strengthens its strategic governance during a phase of accelerated innovation and global expansion. Median’s flagship platform, eyonis®, integrates advanced artificial intelligence and medical imaging science with the goal of improving early cancer detection and enhancing diagnostic accuracy for clinicians worldwide. The Company is also recognized as a leading provider of AI-driven image analysis and central imaging services supporting oncology drug developers in clinical trials across the globe.
With his extensive background in scaling technology-driven healthcare organizations, Cederholm is expected to contribute valuable expertise to guide Median’s continued growth. His experience complements the Company’s mission to transform cancer diagnostics through cutting-edge AI solutions that support earlier intervention and improved patient outcomes.
The appointment reinforces Median Technologies’ commitment to technological excellence, regulatory leadership, and strategic expansion as it continues to advance next-generation AI solutions for oncology imaging and early cancer diagnosis.
